부산대학교 도서관

PBSCs are increasingly being chosen as the mode of donation among unrelated donors. Pediatric patients, in particular, may receive very high CD34+ and CD3+ doses during unrelated PBSCT. In this work, we analyzed survival and GVHD outcomes in a cohort of 81 children who received unrelated PBSCT with uniform antithymocyte globulin (ATG)-based in vivo T-cell depletion for treatment of hematologic malignancy, with emphasis on the impact of cell dose on transplant outcomes. EFS was 61.5±5.6%, with higher CD34+ dose (>10.0 × 106/kg) and lower patient risk status predicting improved survival in multivariate study. Cumulative incidence of relapse was 30.2±5.2%; a low CD34+ dose was the only significant factor for relapse. Neither CD34+ nor CD3+ dose was a significant determinant of acute or chronic GVHD. Importance of CD34+ dose was reaffirmed in a subcohort of younger patients who received greater median cell doses than the overall cohort. In summary, for children who received unrelated PBSCT with ATG-based T-cell depletion for treatment of hematologic malignancy, the CD34+ dose was the most important factor for relapse and EFS, and neither the CD34+ nor the CD3+ dose influenced incidence of acute or chronic GVHD. [ABSTRACT FROM AUTHOR]